期刊文献+

芬布芬对诺氟沙星体内过程的影响

Effects of Co-Administrationof Fenbufen on the Pharmacokinetics of Norfloxacin
原文传递
导出
摘要 目的探讨芬布芬对诺氟沙星体内过程的影响。方法①SD大鼠24只,随机均分4组:诺氟沙星10 mg.kg-1+生理盐水组、诺氟沙星10 mg.kg-1+芬布芬10 mg.kg-1组、诺氟沙星10 mg.kg-1+芬布芬20 mg.kg-1、诺氟沙星10mg.kg-1+芬布芬40 mg.kg-1组。静注诺氟沙星后于不同时间颈静脉取血,HPLC测定诺氟沙星浓度,DAS2.0软件计算药动学参数;②昆明种小鼠40只,随机均分4组:诺氟沙星15 mg.kg-1+生理盐水组、诺氟沙星15 mg.kg-1+芬布芬15 mg.kg-1组、诺氟沙星15 mg.kg-1+芬布芬30 mg.kg-1、诺氟沙星15 mg.kg-1+芬布芬60 mg.kg-1组。尾静脉注射诺氟沙星30 min后处死动物,分离脑组织制备脑组织匀浆,HPLC测定诺氟沙星浓度。结果联用不同剂量芬布芬,诺氟沙星的血药浓度和脑药浓度均未发生明显改变(P>0.05)。结论芬布芬对诺氟沙星的体内过程无明显影响。 OBJECTIVE To investigate the effects of co-administrating fenbufen on the pharmacokinetics of norfloxacin.METHODS 24 Sprague-Dawley rats were randomly divided into 4 groups by norfloxacin 10 mg·kg-1+saline,norfloxacin 10 mg·kg-1+ fenbufen 10 mg·kg-1,norfloxacin 10 mg·kg-1+ fenbufen 20 mg·kg-1,norfloxacin 10 mg·kg-1+ fenbufen 40 mg·kg-1.Blood samples were collected after norfloxacin intravenous injection through vena caudalis.The concentration of norfloxacin was determined by HPLC.Pharmacokinetic parameters were calculated by DAS software V 2.0.On the other hand,40 kunming mice were randomly divided into 4 groups treated by norfloxacin 15 mg·kg-1+saline,norfloxacin 15 mg·kg-1+ fenbufen 15 mg·kg-1,norfloxacin 15 mg·kg-1+ fenbufen 30 mg·kg-1,norfloxacin 15 mg·kg-1+ fenbufen 60 mg·kg-1.The animals were euthanized 30 min after nofloxacin intravenous injection through vena caudalis.The brain tissue was collected and grinded into homogenate.The concentration of norfloxacin was determined by HPLC.RESULTS Co-administrated with fenbufen of different dose,the norfloxacin concentrations both in plasma and in brain homogenate were not effected significantly.CONCLUSION There are no effect of fenbufen on the pamacokinetics of norfloxacin.
出处 《中国药学杂志》 CAS CSCD 北大核心 2010年第14期1085-1088,共4页 Chinese Pharmaceutical Journal
基金 安徽省高校省级自然科学研究计划项目基金(KJ2008B101ZC)
关键词 诺氟沙星 芬布芬 药动学 相互作用 norfloxacin fenbufen pharmacokinetics interaction
  • 相关文献

参考文献7

  • 1LIPSKY B A, BAKER C A. Fluoroquinolone toxicity profiles: a review focusing on new eragents[ J ]. Clin Infect Dis, 1999, 28: 352-364.
  • 2OWENS R C, JRANDAMBROSE P G. Antimicrobialsafety: focus on fl quinol [J]. Clin Infect Dis, 2005,41 ($2) : 144- 157.
  • 3KUSHNER J M, PECKMAN H J, SNYDER C R. Seizures associated with fluoroquinolones [ J ] . Ann Pharmacother, 2001, 35 (10) : 1194-1198.
  • 4SEPCIC K, PERKOVIC O, TUREL I, et al. Adverse effects and interactions of fluoroquinolones [ J ] . Lijec Vjesn, 2009, 131 ( 3- 4) : 74-80.
  • 5SKRETKOWICZ J, GONDKO A. Fluoroquinolones interactions with nonsteroidal anti-inflammatory drugs[ J]. Pol Merkur Lekarski, 2004,16(92) : 194-195.
  • 6AKAHANE K, SEKIGUCHI M, UNE T, et al. Structure-pileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites [ J]. Antirrticrob Agents Chemother, 1989, 33 : 1704-1708.
  • 7KIM J, OHTANI H, TSUJIMOTO M, et al. Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents [ J ]. Drug Metab Pharmacokinet, 2009,24 ( 2 ) : 167-174.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部